This inventor holds 1 USPTO granted patent. Top assignee: University of Virginia Patent Foundation. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Craig J Reist: Innovator in Autoimmune Disease Treatment
Introduction
Craig J Reist is a notable inventor based in Hillsborough, NC (US). He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. His innovative work has led to the development of a unique patent that addresses critical health challenges.
Latest Patents
Craig J Reist holds a patent for "Antigen-based heteropolymers and method for treating autoimmune diseases." This patent involves constructs consisting of antigen-based heteropolymers (AHP's) that include at least one monoclonal antibody specific for binding to the complement receptor (CR1) site on human or non-human primate erythrocytes. The anti-CR1 monoclonal antibody is crosslinked to an antigen specific for a target pathogenic autoantibody. The method provided in this patent offers a novel approach to treating autoimmune diseases in both human and non-human primates using the AHP.
Career Highlights
Craig J Reist is associated with the University of Virginia Patent Foundation, where he continues to advance his research and innovations. His work is characterized by a commitment to improving therapeutic options for patients suffering from autoimmune conditions.
Collaborations
Throughout his career, Craig has collaborated with esteemed colleagues, including Ronald P Taylor and Polly J Ferguson. These partnerships have contributed to the depth and impact of his research in the field.
Conclusion
Craig J Reist's contributions to the treatment of autoimmune diseases through his innovative patent demonstrate his dedication to advancing medical science. His work not only highlights the importance of research in this area but also showcases the potential for new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
